Mercedes Segura Gally, PhD, is Vice President of Process Development at Editas Medicine, where she leads the manufacturing strategy for in vivo gene-editing medicines. With over 20 years of experience in biopharmaceutical development, she has advanced programs from early research through commercial launch across multiple advanced therapeutic modalities. Her expertise spans mRNA and lipid nanoparticle (LNP) technologies, AAV and LVV viral vectors, and cell therapy manufacturing platforms. Previously, she held leadership roles at bluebird bio, AVROBIO, and ElevateBio. At bluebird bio, she contributed to the development and approval of Zynteglo®, Skysona®, Abecma®, and Lyfgenia®. She holds a Pharmacy degree and an MSc in Biotechnology from the Universidad de Buenos Aires, a PhD in Chemical Engineering from Université Laval, and completed postdoctoral research in bioprocessing at Universitat Autònoma de Barcelona, Spain.